Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Medicixi

Novartis building

As promised, Novartis’ Entresto is a ‘slow burner’

Inverts typical sales pattern with faster uptake of the drug in Europe than in the US

- PMLiVE

Novartis kicks back against US corruption charges

Investigation ‘explodes’ with US government information request on 79,000 physicians events

- PMLiVE

IQWiG unimpressed with Cosentyx in two new indications

Concludes Novartis drug has no added benefit in ankylosing spondylitis or psoriatic arthritis

Novartis building

NICE backs Novartis’ Entresto for heart failure

But approves narrower indication than has been authorised by Scotland's SMC

Novartis and Microsoft test Kinect MS tool

The partners have a proof-of-concept for a system that could measure the condition's symptoms

Novartis building

Novartis claims FDA breakthrough status for leukaemia treatment

Designation could speed up development and access for Novartis’ PKC412

- PMLiVE

Novartis makes trio of appointments to senior leadership team

Michael Ball, Vas Narasimhan and Andre Wyss take on new roles

Roche Basel Switzerland

Roche shares slip as profits miss expectations

But shows solid sales growth thanks to its oncology portfolio

- PMLiVE

Novartis continues to expand its NHS eyecare partnerships

Will work with Plymouth Hospitals NHS Trust to improve patient outcomes

Novartis day

Novartis shakes up underperforming Alcon unit

Begins revamp of its business, beginning with changes at its eyecare division

- PMLiVE

Dr George Gunn moves from Novartis to join Nuritas

The Irish biotech also adds to its advisory board

- PMLiVE

Novartis’ Entresto launched in UK

Drug was first CHF therapy to show an improvement over ACE inhibitors

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links